Company Filing History:
Years Active: 2006-2010
Title: Dana Leach: Pioneering Therapeutic Vaccination in Copenhagen
Introduction
Dana Leach, an inventive mind based in Copenhagen, Denmark, has made significant strides in the field of therapeutic vaccination. With three patents to his name, he is recognized for his contributions to immunology, particularly in developing methods that induce cell-mediated immunity against cellular antigens.
Latest Patents
Among his notable inventions are methods for therapeutic vaccination aimed at inducing cytotoxic T-lymphocyte immunity against weak antigens, such as self-proteins. His approach involves antigen presenting cells presenting CTL epitopes of weak antigens alongside foreign T-helper lymphocyte epitopes. These methods have essential applications in cancer treatment, focusing on specific antigens like PSM, Her2, and FGF8b. The technology can be applied through traditional polypeptide vaccination, live attenuated vaccines, or nucleic acid vaccination. Additionally, his latest patents include immunogenic analogues of PSM, Her2, and FGF8b, as well as transformations and nucleic acid molecules encoding these analogues, paving the way for advanced therapeutic solutions.
Career Highlights
Throughout his career, Dana has engaged with prominent companies in the biotherapeutics sector, including Bn Immunotherapeutics, Inc. and Pharmexa A/S. His work has helped pave the way for innovative treatments that harness the body’s immune system to combat diseases, especially cancer.
Collaborations
Dana has collaborated with skilled professionals in the field, including Lucilla Steinaa and Søren Mouritsen. These partnerships have contributed to the success of his patents, combining diverse expertise to push the boundaries of therapeutic vaccination.
Conclusion
Dana Leach’s innovative approaches in the therapeutic vaccination landscape demonstrate the pivotal role of inventors in advancing medical science. His patents and collaborative efforts stand as a testament to the potential of targeted immunotherapy in revolutionizing cancer treatment and enhancing the immune response against disease.